Cargando…
Hereditary Women’s Cancer: Management and Risk-Reducing Surgery
Hereditary women’s syndromes due to inherited mutations result in an elevated risk of developing gynecological cancers over the lifetime of affected carriers. The BRCA 1 and 2 mutations, Lynch syndrome (LS), and mutations in rare hereditary syndromes increase this risk and require more effective man...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967188/ https://www.ncbi.nlm.nih.gov/pubmed/36837501 http://dx.doi.org/10.3390/medicina59020300 |
_version_ | 1784897202473140224 |
---|---|
author | Conte, Carmine Pelligra, Silvia Sarpietro, Giuseppe Montana, Giuseppe Dario Della Corte, Luigi Bifulco, Giuseppe Martinelli, Canio Ercoli, Alfredo Palumbo, Marco Cianci, Stefano |
author_facet | Conte, Carmine Pelligra, Silvia Sarpietro, Giuseppe Montana, Giuseppe Dario Della Corte, Luigi Bifulco, Giuseppe Martinelli, Canio Ercoli, Alfredo Palumbo, Marco Cianci, Stefano |
author_sort | Conte, Carmine |
collection | PubMed |
description | Hereditary women’s syndromes due to inherited mutations result in an elevated risk of developing gynecological cancers over the lifetime of affected carriers. The BRCA 1 and 2 mutations, Lynch syndrome (LS), and mutations in rare hereditary syndromes increase this risk and require more effective management of these patients based on surveillance and prophylactic surgery. Patients need counseling regarding risk-reducing surgery (RRS) and the time required to perform it, considering the adverse effects of premenopausal surgery and the hormonal effect on quality of life, bone density, sexual activity, and cardiological and vascular diseases. Risk-reducing salpingo-oophorectomy (RRSO) is the gold standard for BRCA-mutated patients. An open question is that of endometrial cancer (EC) risk in patients with BRCA1/2 mutation to justify prophylactic hysterectomy during RRSO surgical procedures. RRS provides a 90–95% risk reduction for ovarian and breast cancer in women who are mutation carriers, but the role of prophylactic hysterectomy is underinvestigated in this setting of patients. In this review, we evaluate the management of the most common hereditary syndromes and the benefits of risk-reducing surgery, particularly exploring the role of prophylactic hysterectomy. |
format | Online Article Text |
id | pubmed-9967188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99671882023-02-26 Hereditary Women’s Cancer: Management and Risk-Reducing Surgery Conte, Carmine Pelligra, Silvia Sarpietro, Giuseppe Montana, Giuseppe Dario Della Corte, Luigi Bifulco, Giuseppe Martinelli, Canio Ercoli, Alfredo Palumbo, Marco Cianci, Stefano Medicina (Kaunas) Review Hereditary women’s syndromes due to inherited mutations result in an elevated risk of developing gynecological cancers over the lifetime of affected carriers. The BRCA 1 and 2 mutations, Lynch syndrome (LS), and mutations in rare hereditary syndromes increase this risk and require more effective management of these patients based on surveillance and prophylactic surgery. Patients need counseling regarding risk-reducing surgery (RRS) and the time required to perform it, considering the adverse effects of premenopausal surgery and the hormonal effect on quality of life, bone density, sexual activity, and cardiological and vascular diseases. Risk-reducing salpingo-oophorectomy (RRSO) is the gold standard for BRCA-mutated patients. An open question is that of endometrial cancer (EC) risk in patients with BRCA1/2 mutation to justify prophylactic hysterectomy during RRSO surgical procedures. RRS provides a 90–95% risk reduction for ovarian and breast cancer in women who are mutation carriers, but the role of prophylactic hysterectomy is underinvestigated in this setting of patients. In this review, we evaluate the management of the most common hereditary syndromes and the benefits of risk-reducing surgery, particularly exploring the role of prophylactic hysterectomy. MDPI 2023-02-06 /pmc/articles/PMC9967188/ /pubmed/36837501 http://dx.doi.org/10.3390/medicina59020300 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Conte, Carmine Pelligra, Silvia Sarpietro, Giuseppe Montana, Giuseppe Dario Della Corte, Luigi Bifulco, Giuseppe Martinelli, Canio Ercoli, Alfredo Palumbo, Marco Cianci, Stefano Hereditary Women’s Cancer: Management and Risk-Reducing Surgery |
title | Hereditary Women’s Cancer: Management and Risk-Reducing Surgery |
title_full | Hereditary Women’s Cancer: Management and Risk-Reducing Surgery |
title_fullStr | Hereditary Women’s Cancer: Management and Risk-Reducing Surgery |
title_full_unstemmed | Hereditary Women’s Cancer: Management and Risk-Reducing Surgery |
title_short | Hereditary Women’s Cancer: Management and Risk-Reducing Surgery |
title_sort | hereditary women’s cancer: management and risk-reducing surgery |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967188/ https://www.ncbi.nlm.nih.gov/pubmed/36837501 http://dx.doi.org/10.3390/medicina59020300 |
work_keys_str_mv | AT contecarmine hereditarywomenscancermanagementandriskreducingsurgery AT pelligrasilvia hereditarywomenscancermanagementandriskreducingsurgery AT sarpietrogiuseppe hereditarywomenscancermanagementandriskreducingsurgery AT montanagiuseppedario hereditarywomenscancermanagementandriskreducingsurgery AT dellacorteluigi hereditarywomenscancermanagementandriskreducingsurgery AT bifulcogiuseppe hereditarywomenscancermanagementandriskreducingsurgery AT martinellicanio hereditarywomenscancermanagementandriskreducingsurgery AT ercolialfredo hereditarywomenscancermanagementandriskreducingsurgery AT palumbomarco hereditarywomenscancermanagementandriskreducingsurgery AT ciancistefano hereditarywomenscancermanagementandriskreducingsurgery |